Povorcitinib-d6

• Description:

  Povorcitinib-d6 (INCB54707-d6) is the deuterium labeled Povorcitinib (HY-145588) . Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) [1][2].

• Product Name Alternative:

  INCB54707-d6

• UNSPSC:

  12352211

• Target:

  Isotope-Labeled Compounds; JAK

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Others; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research:

  Inflammation/Immunology

• Smiles:

  N#CCC1(N2C=C(C3=C(C([2H])([2H])[2H])NN=C3C([2H])([2H])[2H])C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1

• Molecular Formula:

  C23H16D6F5N7O

• Molecular Weight:

  513.50

• References & Citations:

  [1]Paul Smith, et al. Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) . Patent WO2021076124A1.|[2]Kirby JS, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J Am Acad Dermatol. 2023 Oct 21:S0190-9622 (23) 03037-2.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Isotope-Labeled Compounds

• Clinical Information:

  No Development Reported

• CAS Number:

  [3029304-24-0]